{"brief_title": "Study to Determine the Safety and Preliminary Efficacy of CC-1088 in the Treatment of Myelodysplastic Syndromes", "brief_summary": "The primary objective of the study is to assess the safety of CC-1088 to patients with myelodysplastic syndromes (MDS).", "condition": "Myelodysplastic Syndrome", "intervention_type": "Drug", "intervention_name": "CC-1088", "criteria": "- Eligible patients must have a diagnosis of MDS of at least 12 weeks that is not therapy related. - Patient must be able to adhere to the study visit schedule and other protocol requirements. - Patient must understand and voluntarily sign an informed consent document. - Women of childbearing potential (WCBP) must have a negative serum or urine pregnancy test. - Women must not be pregnant or lactating.", "gender": "All", "minimum_age": "18 Years", "maximum_age": "80 Years", "healthy_volunteers": "No", "id": "NCT00045786.xml"}